W. Walsh

发表

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

Eric Sauerbrei, Stephen Chia, Karen A Gelmon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-21 has activity in patients with metastatic melanoma: a phase II study.

Bingshu E. Chen, K. Savage, K. Bélanger, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer 1

E. Eisenhauer, A. Tolcher, W. Walsh, 2002 .

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)

R. Gascoyne, E. Eisenhauer, W. Walsh, 2011, Leukemia & lymphoma.

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

E. Eisenhauer, K. Gelmon, H. Hirte, 2004, Investigational New Drugs.

A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

A. Oza, L. Seymour, L. Siu, 2006, Cancer Chemotherapy and Pharmacology.

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

L. Seymour, H. Hirte, W. Miller, 2005, Investigational New Drugs.

A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.

K. Gelmon, D. Ayers, L. Seymour, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer

M. Gleave, E. Eisenhauer, H. Hirte, 2008, Clinical Cancer Research.

The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group

E. Eisenhauer, A. Oza, M. Carey, 2004, International Journal of Gynecologic Cancer.

Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.

E. Eisenhauer, J. Wright, W. Walsh, 2009, Clinical lymphoma & myeloma.

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, J. Wright, J. Wright, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.

I. Tannock, L. Seymour, M. Moore, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgical salvage of chemorefractory germ cell tumors.

L. Einhorn, W. Walsh, J. Messemer, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors

N. Munshi, G. Sledge, L. Einhorn, 1992, Investigational new drugs.

Phase I and pharmacology study of intravesical mitoxantrone for recurrent superficial bladder tumors.

W. Walsh, J. Maroun, D. Stewart, 1990, The Journal of urology.

A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.

E. Eisenhauer, A. Tolcher, W. Walsh, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer

D. Tu, W. Parulekar, L. Siu, 2010, Cancer.

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

L. Seymour, H. Hirte, M. Moore, 2005, Urologic oncology.

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

E. Eisenhauer, A. Oza, H. Hirte, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group

E. Eisenhauer, Christina R. Lee, W. Walsh, 2011, Leukemia & lymphoma.

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

E. Eisenhauer, W. Walsh, A. Colevas, 2004, Investigational New Drugs.

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.

L. Seymour, S. Ellard, W. Walsh, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer

E. Eisenhauer, K. Gelmon, L. Seymour, 2009, Clinical Cancer Research.

A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130

K. Bélanger, K. Gelmon, L. Seymour, 2005, Investigational New Drugs.

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.

L. Seymour, F. Shepherd, D. Tu, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186

B. Leber, E. Eisenhauer, S. Kamel‐Reid, 2013, Leukemia & lymphoma.

An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin

L. Seymour, W. Walsh, C. Lathia, 2004, Investigational New Drugs.

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

L. Seymour, D. Hedley, M. Moore, 2012, Investigational New Drugs.

A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours

E. Eisenhauer, L. Siu, W. Walsh, 2007, Investigational New Drugs.

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

E. Eisenhauer, H. Hirte, A. Razak, 2011, British Journal of Cancer.

Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.

E. Eisenhauer, A. Oza, J. Dancey, 2013, Gynecologic oncology.

Common toxicity criteria: The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) experience

E. Eisenhauer, M. Brundage, W. Walsh, 1992 .

Phase I-II trial of daily thalidomide in combination with docetaxel in patients with relapsed non-small cell lung cancer: A final analysis.

W. Walsh, J. Rooney, S. Khanani, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98)

L. Seymour, W. Walsh, G. Bjarnason, 2004, Investigational New Drugs.

A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).

E. Eisenhauer, M. Tsao, O. Ludkovski, 2012 .

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

Christopher Poole, Tien Le, Susan Ellard, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129.

K. Gelmon, L. Seymour, B. Norris, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC).

H. Mackay, E. Eisenhauer, A. Oza, 2012 .

Phase II Trial of OGX-011 in Combinationwith Docetaxel in Metastatic Breast Cancer

E. Eisenhauer, K. Gelmon, L. Seymour, 2009 .

A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours.

S. Bates, L. Seymour, W. Walsh, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Performance of multinomial designs in comparison with response-based designs in non-randomized phase II trials of targeted cancer agents.

D. Lacombe, E. Eisenhauer, D. Tu, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.